Cencora, Inc. $COR Shares Sold by Private Management Group Inc.

Posted by Francis Steltz on Aug 30th, 2026

Private Management Group Inc. decreased its holdings in shares of Cencora, Inc. (NYSE:COR – Free Report) by 24.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,041 shares of the company’s stock after selling 5,000 shares during the period. Private Management Group Inc.’s holdings in Cencora were worth $4,256,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. ExodusPoint Capital Management LP bought a new position in Cencora during the 4th quarter worth $16,487,000. Impact Partnership Wealth LLC bought a new stake in Cencora in the first quarter valued at $1,170,000. Deutsche Bank AG bought a new stake in Cencora in the second quarter valued at $286,673,000. SEB Asset Management AB acquired a new position in shares of Cencora during the first quarter valued at $134,139,000. Finally, PFA Pension Forsikringsaktieselskab acquired a new position in shares of Cencora during the fourth quarter valued at $59,145,000. 97.52% of the stock is currently owned by institutional investors.

Cencora Price Performance

Shares of NYSE COR opened at $322.12 on Friday. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The firm’s 50-day simple moving average is $307.38 and its 200 day simple moving average is $310.88. The company has a quick ratio of 0.58, a current ratio of 0.93 and a debt-to-equity ratio of 3.53. The stock has a market cap of $61.47 billion, a P/E ratio of 23.93, a P/E/G ratio of 1.85 and a beta of 0.57.

Cencora (NYSE:COR – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $4.48 earnings per share for the quarter, topping the consensus estimate of $4.35 by $0.13. The business had revenue of $84.75 billion during the quarter, compared to the consensus estimate of $84.31 billion. Cencora had a net margin of 0.79% and a return on equity of 125.45%. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.00 earnings per share. Equities analysts expect that Cencora, Inc. will post 17.87 EPS for the current year.

Cencora announced that its Board of Directors has approved a stock repurchase program on Thursday, May 21st that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the company to repurchase up to 3.9% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s management believes its shares are undervalued.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Friday, August 14th will be issued a $0.60 dividend. The ex-dividend date is Friday, August 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is 17.83%.

Insider Activity at Cencora

In other Cencora news, EVP Elizabeth S. Campbell sold 11,300 shares of the company’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $324.12, for a total value of $3,662,556.00. Following the completion of the sale, the executive vice president directly owned 19,455 shares in the company, valued at $6,305,754.60. This represents a 36.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Lauren M. Tyler purchased 550 shares of the firm’s stock in a transaction on Monday, June 22nd. The shares were purchased at an average cost of $270.23 per share, with a total value of $148,626.50. Following the completion of the purchase, the director owned 4,359 shares in the company, valued at $1,177,932.57. This represents a 14.44% increase in their position. The disclosure for this purchase is available in the SEC filing. 0.38% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Bank of America increased their price objective on shares of Cencora from $280.00 to $285.00 and gave the stock a “neutral” rating in a report on Wednesday, June 24th. Citigroup reissued a “buy” rating on shares of Cencora in a research note on Thursday, August 6th. UBS Group upped their target price on shares of Cencora from $412.00 to $430.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Barclays dropped their price target on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 10th. Finally, Weiss Ratings raised Cencora from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, August 6th. Thirteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Cencora currently has an average rating of “Moderate Buy” and an average target price of $370.85.

View Our Latest Research Report on COR

Cencora Company Profile

(Free Report)

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.